Tenderwize
Retour à la recherche

Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 185 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

60/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

60 / 100

Complexité

20 / 100

Facteurs de risque

The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...

Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Pharmaceutical discount contract for Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
  • Supply of the drug under uniform conditions set by TK
Afficher le résumé complet

Open House procedure by Techniker Krankenkasse (TK) for discount contracts on the drug Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) under §130c SGB V. The procedure allows continuous joining during the contract term (max 24 months from March 2025 to February 2027). No estimated value provided; no competition or award criteria; eligibility requires being a pharmaceutical entrepreneur with authorization for the drug. Submission is by email (with qualified electronic signature) or post. Documents are available but were not analyzed.

Risques

The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...

Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG with respect to the offered drug
  • Must have a valid marketing authorization for the drug in Germany or be otherwise entitled to market it

Eligibility

  • Must provide a self-declaration confirming eligibility and no exclusion grounds

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; contract is awarded to all eligible participants who meet requirements.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

Discount contracts for the combination drug Bictegravir/Emtricitabin/Tenofoviralafenamid. Continuous enrollment; no exclusivity; standard conditions.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Feb 2025 - Feb 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; contract is awarded to all eligible participants who meet requirements.

Date limite

Deadline Feb 27, 2027

Détails de la procédure

Date de publication
19 Jan 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
39458-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3